Vancouver, British Columbia – September 03, 2021 – Blackhawk Growth Corp. (CSE:BLR) (CNSX:BLR.CN) (Frankfurt:0JJ) (the “Company” or “Blackhawk”) has completed its previously announced investment in MindBio Therapeutics Pty Ltd. (“MindBio Therapeutics”).  

“I am extremely excited to see us complete this transaction” says Frederick Pels, CEO of Blackhawk. “I look forward to working with the team at MindBio and building substantial value for our shareholders over the coming quarters.”

The Transaction

Pursuant to the terms of a share purchase agreement, dated August 30, 2021, the Company has acquired all of the outstanding share capital of 1286409 B.C. Ltd. (the “Parent”), of which MindBio Therapeutics is a wholly-owned subsidiary, and has issued 22,095,180 common shares to the existing shareholders of the Parent at a deemed price of $0.38 per share. Half of these shares are subject to restrictions on resale for a period of four-months-and-one-day following issuance. No finders’ fees or commissions were paid in connection with closing of the acquisition.

The Company is at arm’s length from the Parent, MindBio Therapeutics and its shareholders. The transaction neither constitutes a fundamental change nor a change of business for the Company, nor has it resulted in a change of control of the Company within the meaning of applicable securities laws and the policies of the Canadian Securities Exchange.  In connection with completion of the transaction, the Company will not be assuming any additional debts or obligations.

MindBio Therapeutics now forms part of the Company’s existing portfolio of investments in the health care sector.  MindBio Therapeutics’s existing board and directors will continue to retain responsibility for overseeing day-to-day operations.

About MindBio Therapeutics

MindBio Therapeutics is an arms-length privately held clinical stage drug development company that is pioneering psychedelic micro-dosing research and is advancing emerging therapies to treat a range of debilitating health conditions such as depression, anxiety, chronic pain, cognitive impairment and PTSD.

In a world’s first clinical trial of its kind, MindBio Therapeutics has started Phase 1 clinical trials at the University of Auckland in New Zealand, in a safety study of 80 participants micro-dosing LSD to patients.  The study has received regulatory approval and government funding for the importing of LSD, laboratory work using the drug and approvals for participants to be prescribed the drug and then patients take the drug at home as they would any other medication.  Approvals have also been received for Phase 2 clinical trials involving micro-dosing LSD in late-stage cancer patients experiencing end of life distress.  

MindBio Therapeutics is also pioneering the development of micro-dose formulations and a range of technology and artificial intelligence applications to ensure the safe dosage, use and administration of psychedelic medicines in the community.  Early indications show that LSD is tolerated well in micro-doses and has a lower side effect profile than the currently prescribed anti-depressant drugs.

MindBio Therapeutics completed an equity financing for proceeds of approximately AUD$1,300,000, which gives it sufficient working capital to complete Phase 1 clinical trials. Completion of this financing was critical for Blackhawk to ensure MindBio Therapeutics was properly capitalized prior to the acquisition..

MindBio Therapeutics Management Team:

Gavin Upiter – Chairman

Gavin has over 25 years of experience leading companies in the pharmaceutical sector.  Engineering qualified, prior to founding Generic Health, a leading generic pharmaceutical company which was sold to Lupin Pharmaceuticals, (NSE: LUPIN), Gavin started his executive career at Bristol Myers Squibb.  He was Australian CEO of Amneal Pharmaceuticals (NYSE: AMRX) and Executive Director of Slade Health, Australia’s leading hospital pharmacy chain.  Gavin founded Directo, Australia’s first online pharmaceutical B2B marketplace for pharmacies and suppliers.

Dr. Zena Burgess, PhD. FAICD,FAPS – Non-Executive Director

Zena has a strong interest in the future of health care. She serves as the Chief Executive Officer of the Australian Psychologists Society and formerly as Chief Executive of the Royal Australian College of General Practitioners. She is a member of the international advisory board of Connext2MyDoctor and the telehealth influencers alliance. She is also a director of the Australian Patients Association and Chair of the board subcommittee on governance and risk of the Victorian Farmers Federation. Zena has substantial experience serving on boards of government entities. She holds a PhD in psychology from the Australian Catholic University and a Master of Business Administration from Monash University and a Master of Education from La Trobe University. She has a wealth of experience in health changes and strategic advocacy to governments.

Justin Hanka – Co-Founder & Director

Justin Hanka is in investment banking and financing of mergers and acquisitions and capital markets transactions.  He is Non-Executive Director of EonX (CSE:EONX), a financial technology company, Non-Executive Director of Goldcar, (a Europcar Company listed on the Euronext in France), Non-Executive Director of The Digital Tribes Company, an IT digital transformation company headquartered in Sweden.  He is an experienced executive having served as Chief Operating Officer for iSelect (ASX: ISU) and having sold Helpmechoose as its CEO to Mortgage Choice (ASX:MOC).  Justin’s expertise spans the pharmaceutical and health sector including pharmaceuticals, pharma-technologies, fin-techs, digital transformation and technology, influencer marketing, health and wellness, entertainment and ecommerce.

Colin Keating – Chief Executive Officer

Colin is an experienced CEO and Managing Director having led publicly listed Hogg Robinson Group Australia (LSE) and BuyMyPlace (ASX), both large private technology led organisations and has also held senior global leadership positions with the likes of American Express. With over 25 years experience in both established and scale up businesses, Colin possesses a demonstrable track record in driving growth, shaping organisational culture and delivering shareholder value. His experience is broad and varied having worked across multiple industries including Financial Services & Payments, Corporate Travel, Property Tech, Health Tech, Data Management and Wealth Management. Colin also has deep experience working in, and advising, organisations on strategic initiatives such as capital raising, M&A activities, IPO’s and exit strategies. Having worked in the United Kingdom, Hong Kong and the US, Colin’s global experience will be of enormous benefit to Mind Therapeutics as the business grows both domestically and across international markets.

Scientific Team:

Dr Suresh Muthukumaraswamy, PhD BSc Hons – Lead Scientist

Suresh is an Associate Professor of Psychopharmacology in the Faculty of Medical and Health Sciences at the University of Auckland.  Suresh’s main research interests are in understanding how therapies alter brain activity and in developing methodologies to measure these changes in both healthy individuals and patient groups – particularly those with depression. His previous studies have involved a range of compounds including hallucinogens (ketamine, LSD, psilocybin), anesthetics (propofol, dexmedetomidine), anti-epileptics (vigabatrin, perampanel, tiagabine) and GABA-enhancers (zolpidem, gaboxadol).

He is currently leading clinical trials investigating LSD microdosing and other new antidepressant therapies. Suresh has published over 100 scientific papers in the field of psychopharmacology and neuroimaging which have been cited over 6500 times. Suresh has received several awards including a prestigious Rutherford Discovery Fellowship and several grants from the Health Research Council of New Zealand.

Dr Nicholas Hoeh, MD.Am.BD.Cert Psych, – Psychiatrist

Nick is a consultant psychiatrist working part time at the Auckland District Health Board and in private practice.  Additionally, he is a professional teaching fellow in Psychological Medicine at the University of Auckland. He obtained his medical degree at the University of Medicine and Dentistry in New Jersey and completed his internship, psychiatry residency, and old age psychiatry fellowship at the University of Pennsylvania in Philadelphia. Nick’s current research interests include the clinical use of repetitive transcranial magnetic stimulation and psychedelics for treatment resistant depression.

Dr Rachael Sumner, PhD.Pharma. MSc Hons. BA. Hons. Psych – Clinical Research Associate

Dr Sumner is a leading researcher in the field of psychedelics and has been involved in numerous research studies in her work at the University of Auckland.  Notable studies include the use of Ketamine in the treatment of depression and the overarching aim and application of Dr Sumner’s research is to validate non-invasive electrophysiological assays of brain function in neurological and psychiatric health and disease.

Dr Frederick Sundram, PhD. MSc. MA. FRCPsych(UK). MB BCh. BAO; B.MedSc. – Psychiatry & Technology Consultant

Frederick is an Associate Professor at the Department of Psychological Medicine at the University of Auckland and a Consultant Liaison Psychiatrist at North Shore Hospital.  Previously he was research fellow at the Department of Forensic and Neurodevelopmental Science at the Institute of Psychiatry, King’s College London and the Royal College of Surgeons in Ireland where he completed his PhD in Neuroimaging. Frederick also completed a Masters in Healthcare Management at the Institute of Public Administration, Dublin and a Masters in Healthcare Informatics. His research interests include depression, neuroimaging, self-harm/suicide, medical education, overlap between medicine and psychiatry, medically unexplained physical symptoms and healthcare informatics.

Dr Partha Roop, PhD. M.Tech. BEng. – AI & Machine Learning

Partha’s research interests are in Digital Health, Formal Methods for Safety-Critical applications of AI and Machine Learning, and Real-Time Systems. Partha is working with colleagues from the Medical School and the Auckland Bioengineering Institute (ABI) on new techniques developed by his group known as organ on a chip. He is also interested in heart rate variability and Biofeedback.

Blackhawk would like to encourage all investors and interested parties to take a look at a MindBio Therapeutics’ recently uploaded video here: as well as their corporate website which can be found here:

About Blackhawk Growth

Blackhawk is an investment holding looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes Sac Pharma, LeichtMind Clinics, Noble Hemp, Spaced Food and NuWave Foods. Blackhawk continues to bring its investments to cash flow and is growing at an exceeding pace.

The Company diligently posts updates through videos from the official company YouTube channel  

Please join the conversation on our Blackhawk group supporter’s telegram group at and visit us online at

For further information please contact:

Frederick Pels, Chief Executive Officer


This email address is being protected from spambots. You need JavaScript enabled to view it.

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to transaction and future operations of MindBio Therapeutics Pty Ltd. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.